TY - JOUR
T1 - Irritable bowel syndrome
T2 - The burden and unmet needs in Europe
AU - Quigley, E. M.M.
AU - Bytzer, P.
AU - Jones, R.
AU - Mearin, F.
N1 - Funding Information:
The authors would like to acknowledge the editorial support and contribution of ACUMED ® to this manuscript. ACUMED's contribution and this research were funded by Novartis Pharma AG.
Funding Information:
Grant support: This paper was funded by Novartis Pharma AG.
Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2006/10
Y1 - 2006/10
N2 - Irritable bowel syndrome affects approximately 10-15% of the European population, although prevalence rates vary depending on the classification used and the country surveyed. This may be due to differences in patterns of medical care and diagnosis of the condition. Up to 70% of individuals with irritable bowel syndrome may not have been formally diagnosed. The disorder affects 1.5-3 times as many women as men and poses a significant economic burden in Europe, estimated at €700-€1600 per person per year. It also reduces quality of life and is associated with psychological distress, disturbed work and sleep, and sexual dysfunction. It is a chronic disorder, which affects many individuals for more than 10 years. Most patients are managed in primary care, although some are referred to gastroenterologists and other specialists. Patients with irritable bowel syndrome undergo more abdomino-pelvic surgery than the general population. We propose that a positive diagnosis of the condition may avoid the delay in diagnosis many patients experience. We conclude that, in Europe, there are significant unmet needs including lack of familiarity with irritable bowel syndrome, difficulties in diagnosis and lack of effective treatments for the multiple symptoms of the disorder. The development of pan-European guidelines for irritable bowel syndrome will benefit patients with this condition in Europe.
AB - Irritable bowel syndrome affects approximately 10-15% of the European population, although prevalence rates vary depending on the classification used and the country surveyed. This may be due to differences in patterns of medical care and diagnosis of the condition. Up to 70% of individuals with irritable bowel syndrome may not have been formally diagnosed. The disorder affects 1.5-3 times as many women as men and poses a significant economic burden in Europe, estimated at €700-€1600 per person per year. It also reduces quality of life and is associated with psychological distress, disturbed work and sleep, and sexual dysfunction. It is a chronic disorder, which affects many individuals for more than 10 years. Most patients are managed in primary care, although some are referred to gastroenterologists and other specialists. Patients with irritable bowel syndrome undergo more abdomino-pelvic surgery than the general population. We propose that a positive diagnosis of the condition may avoid the delay in diagnosis many patients experience. We conclude that, in Europe, there are significant unmet needs including lack of familiarity with irritable bowel syndrome, difficulties in diagnosis and lack of effective treatments for the multiple symptoms of the disorder. The development of pan-European guidelines for irritable bowel syndrome will benefit patients with this condition in Europe.
KW - Europe
KW - Healthcare burden
KW - Irritable bowel syndrome
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=33748561834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748561834&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2006.05.009
DO - 10.1016/j.dld.2006.05.009
M3 - Short survey
C2 - 16807154
AN - SCOPUS:33748561834
SN - 1590-8658
VL - 38
SP - 717
EP - 723
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
IS - 10
ER -